MAT Training Exam Questions And Answers

MAT Training Exam Questions And Answers 1. When making recommendation forMAT for persons with Opioid Use Disorder, which of the following should be included as a part of informed consent? A. Patients should be advised of risks, benefits and alternatives of the available MATs for OUD. B. Risk-benefit discussion should be documented in the medical record. C. Specific consent form is not required, but some providers or treatment programs may use this approach to optimize documentation and communication with patients, and to manage expectations. D. A, B, C Individualizing psychosocial treatment includes targeted areas of clinical concern. Which of the following are targets areas of clinical concern when providing individualized psychosocial treatment when providing MAT? A. All patients receiving OUD MAT are at risk for relapse to opioid use and require interventions for reduction in relapse risk B. Risk of relapse decreases with: −Length of time abstinent from opioids−Abstinence from other substance use−Level of psychosocial functioning (e.g., employment, absence of criminal activity) C. As risk of relapse reduces, intensity and type of psychosocial treatment may lessen D. Other psychiatric co-occurring conditions require clinical attention E. Job training and education referrals should be considered F. B, C, and D G. A, B, C, D, and E H. A, B, and C Which of the following are regulatory criteria for methadone? A. At least 8 urine drug tests per year. B. Urine drug testing as clinically appropriate − Initial evaluation; more frequent at onset of treatment or when clinically indicated; less frequent in long-term stable maintenance. C. Clinical visit frequency- ruling by CSAT depending on length in treatment and clinical status. D. Clinical visit frequency as clinically appropriate. E. Number of days supply of medication progressively increases over first 2 years of treatment, with maximum of one month supply. F. Number of days supply of medication determined as clinically appropriate, schedule III permits refills up to 6 months. G. A, C & E H. B, D & F I. A, D & E Which of the following are regulatory criteria for buprenorphine? A. At least 8 urine drug tests per year. B. Urine drug testing as clinically appropriate − initial evaluation; more frequent at onset of treatment or when clinically indicated; less frequent in long-term stable maintenance. C. Clinical visit frequency ruling by CSAT depending on length in treatment and clinical status. D. Clinical visit frequency as clinically appropriate.